MyeloPro is a research stage biopharmaceutical company, aiming to develop innovative therapeutics for the treatment of blood diseases. The founders have cumulated unique expertise and know-how in
the area of myeloproliferative neoplasms. A major milestone was entering into an exclusive, global license agreement with CeMM to develop treatments targeting mutated calreticulin.
